What are the best treatments for McCune Albright?

Treatment for McCune-Albright syndrome is highly individualized, focusing on managing the specific endocrine, skeletal, and dermatological manifestations rather than a single curative therapy. Current care relies on a multidisciplinary approach using pharmacological agents to control hormone overproduction, combined with surgical interventions for fibrous dysplasia and comprehensive monitoring by specialized medical teams.

How is McCune-Albright syndrome managed medically?

Because McCune-Albright syndrome (MAS) presents with a wide spectrum of symptoms—including fibrous dysplasia of the bone, café-au-lait skin spots, and hyperfunctioning endocrine glands—treatment must be tailored to the specific needs of the patient. There is no single medication that treats all symptoms; instead, clinicians focus on the primary drivers of disease activity. For hyperthyroidism, antithyroid medications such as methimazole are commonly used. In cases of precocious puberty, aromatase inhibitors like letrozole (Femara) are frequently prescribed to slow bone age advancement and manage the early onset of puberty. For patients with excess growth hormone, somatostatin analogs like octreotide (Sandostatin) may be considered, though their effectiveness varies significantly between individuals.

What non-pharmacological and surgical treatments are available?

Surgical intervention is often necessary for the skeletal complications of McCune-Albright syndrome, particularly when fibrous dysplasia causes pain, deformity, or structural instability. Common approaches include:

• Orthopedic surgery: Procedures such as curettage and bone grafting, or the use of internal fixation devices (rods or plates) to stabilize affected bones and prevent fractures.


• Physical and occupational therapy: Essential for maintaining range of motion, strengthening muscles surrounding affected bones, and adapting daily activities to accommodate physical limitations.


• Craniofacial surgery: Specialized procedures may be required if fibrous dysplasia affects the facial or skull bones, potentially impacting vision or hearing.

Which specialists are required for a multidisciplinary team?

Effective management of McCune-Albright syndrome requires a coordinated team of experts who understand the rarity and complexity of the condition. Patients typically require care from a pediatric or adult endocrinologist to manage hormone levels, an orthopedic surgeon specializing in bone dysplasia to monitor skeletal health, and a geneticist to provide counseling and coordinate care. Depending on the patient's specific presentation, the team may also include a neurologist, an ophthalmologist (if facial bones are involved), and a physical therapist.

Are there emerging treatments for McCune-Albright syndrome?

Research into McCune-Albright syndrome is ongoing, with significant interest in understanding the GNAS gene mutation that causes the disease. While no cure currently exists, clinical researchers are investigating the long-term efficacy of bisphosphonates for bone pain management, although data remains mixed regarding their ability to alter the progression of fibrous dysplasia. Participation in clinical trials remains a vital way for some patients to access emerging therapies and contribute to the collective understanding of this rare condition.

Next steps

• Consult with a tertiary care center that has experience treating rare endocrine and bone disorders.


• Connect with the 62 members of the McCune-Albright syndrome community on DiseaseMaps.org to share experiences and coping strategies.


• Maintain a comprehensive symptom diary to share with your multidisciplinary medical team during appointments.


• Regularly screen for endocrine complications, as hormone levels can fluctuate throughout the lifespan of a patient with McCune-Albright syndrome.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; all treatment decisions must be made in consultation with your personal healthcare team.

References

• NIH Genetic and Rare Diseases Information Center (GARD): McCune-Albright syndrome overview.


• Orphanet: Expert-authored clinical information on McCune-Albright syndrome.


• OMIM (Online Mendelian Inheritance in Man): Molecular basis and genetic data for MAS.


• The MAGIC Foundation: Support and resources for endocrine-related rare diseases.